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aa  amino acids 
ĮC  carboxy terminal end of the fibrinogen Į-chain
ADP  adenosine diphosphate 
CHD  coronary heart disease 
CRP  C-reactive protein 
EDTA  ethylene-diamine-tetra-acetic acid 
FgDP  fibrinogen degradation products 
FnDP  fibrin degradation products 
FPA  fibrinopeptide A 
FPB  fibrinopeptide B 
HMW  high molecular weight 
IHD  ischemic heart disease 
IL-1  interleukin 1 
IL-6  interleukin 6 
ISTH  international society of thrombosis and haemostasis 
kDa  kiloDalton 
LMW  low molecular weight 
LMW`  very low molecular weight 
LPS  lipopolysaccharid 
M  molar 
mPa.s  millipascal seconds 
MW  molecular weight 
N-terminal amino-terminal 
PAGE  polyacrylamid gel electrophoresis 
PAI  plasminogen activator inhibitor 
PBMC  peripheral blood mononuclear cells 
PBS  phosphate buffered saline 
RNA  ribonucleic acid 
SDS  sodium dodecyl sulphate 
7SD  standard deviation 
TAFI       thrombin-activatable fibrinolysis inhibitor 
TF  tissue factor 
TNF  tumor necrosis factor 
U-PA urokinase-type plasminogen activator
U  unit 
vWF  von Willebrand Factor 
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94. GENERAL INTRODUCTION 
Fibrinogen is a large, soluble glycoprotein. It plays a central role in human hemostasis 
through its conversion to fibrin in the last step of the coagulation cascade, and by its 
essential role in platelet aggregation.  Normal plasma concentration is 1.7-4.0 g/l. Being 
an acute-phase protein, the concentration rises rapidly during inflammatory conditions, 
major surgery and certain cancer forms (1-3). The plasma concentration results from a 
complex interaction between genetic and environmental factors (4). Plasma fibrinogen 
levels are higher in females than in males, and increased concentrations are found in 
postmenopausal women, smokers, patients with diabetes, obesity, hypercholesterolemia 
and hypertension (5). Factors which may decrease fibrinogen levels include physical 
exercise, weight loss, moderate alcohol consumption and smoking cessation (4;6-10).  
Treatment with fibrates and platelet aggregation inhibiting drugs such as ticlopidine may 
lower plasma levels of fibrinogen (11). Different responses of hormone replacement 
therapy have been reported (9;12-14). Genetic heritability accounts for about 50% of the 
variance in fibrinogen concentration between individuals (15). 
Structure
In 1959 Hall and Slayter produced electron microscopy images of fibrinogen revealing a 
rod-like molecule with 3 interconnected globules (16). The length was estimated to be 
475 r 25 Å. The diameter of the center globule was approximately 50 Å, and the distal 
globules were approximately 65 Å (16;17). The structure was later confirmed by other 
investigators (18;19). Using atomic force microscopy, Marchant and colleagues obtained 
three dimensional images of fibrinogen molecules under aqueous conditions, showing a 
mixture of monomers, dimers and trimeric structures linked through D-D globular 
interconnections (20). 
The fibrinogen molecule is a dimer consisting of 3 pairs of the non-identical polypeptide 
chains AĮ, Bȕ and Ȗ with molecular weight 340 kDa (21). The nomenclature (AĮ,Bȕ,Ȗ)2
reflects the peptides A and B cleaved from fibrinogen by thrombin and the longer Į-, ȕ-
and Ȗ-chains. No peptides are split from the Ȗ-chain during the conversion of fibrinogen 
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to fibrin. The total number of amino-acids is 2964, and the complete amino-acid 
Figure 1. Electron microscope images showing fibrinogen molecules with a central (E)- 
and two peripheral (D) regions (1A), fibrin protofibrils with half-staggered overlapping 
fibrin monomers (1B), and thicker, branching fibrin fibers (1C). Reproduced from Weisel 
(22).
sequence was presented in 1980 by Henschen and Lottspeich (23;24). The molecular 
weights of the individual chains are 66.5 kDa, (610 amino-acids), 52 kDa (461 amino-
acids), and 46.5 kDa (411 amino-acids) for the AĮ-, Bȕ- and Ȗ-chain, respectively 
(25;26). The 6 polypeptide chains are gathered in the central E region (E-domain) (27), 
which is connected to the 2 D regions (D-domains) of the molecule by the 
“interconnector”, comprising 111-112 amino acids of the AĮ-, Bȕ-, and Ȗ-chains joined 
together in a coiled-coil (28) (figure 2). The D region can be further divided into a distal 
nodule containing the C-terminal part of the Ȗ-chain (ȖC), and the proximal nodule 
including the C-terminal Bȕ-chain. The C-terminal part of the AĮ-chain (ĮC) consists of 
an elongated polypeptide extending from the D region, interacting with the central E 
region, and forming intra-molecular ĮC-ĮC connections (29;30). 
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Figure 2. Schematic drawing of the fibrinogen molecule showing the N- and C-terminal 
ends of the AĮ-, Bȕ-, and Ȗ-chains. The coiled-coil regions are illustrated with diagonal 
lines, and disulfide bonds marked with solid lines. CHO indicates carbohydrate 
attachment sites, and P and T represent major cleavage sites for plasmin and thrombin, 
respectively. Adapted from Hantgan (31).
Calcium
Calcium is important for the structural integrity and function of the fibrinogen molecule. 
High affinity binding sites for calcium are located in the Ȗ-chain at Asp318, Asp320, Gly324
and Phe322. In addition several low affinity calcium binding sites exists which are less 
well defined (32). In plasma the binding sites are usually occupied providing protection 
from enzymatic degradation (33;34). 
Disulphide bonds 
Twenty nine disulfide chains located in the AĮ- (8), Bȕ- (11) and Ȗ-chains (10) hold the 6 
chains together (35).  The central E-region contains the 2 pairs of A and B peptides 
linked together by three inter-chained disulfide bonds, 1 between the AĮ-chains and 2 
between the Ȗ-chains. One disulfide bridge links the AĮ- and the Bȕ-chain.
Carbohydrate chains
Fibrinogen is a glycoprotein containing four oligosaccharides located at Bȕ364 and Ȗ52 and 
linked through N-glycosyl bonds. The Į-chain contains no carbohydrate side chains (36). 
The carbohydrate chains are of major importance for the solubility of fibrinogen, and 
modifications of the carbohydrate chains affect the fibrin polymerization properties and 
clot structure. Fibrinogen contains equal amounts of mono- and disialicated chains, and 
variations of the sialic-acid content of the carbohydrate chains account for some of the 
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heterogeneity of fibrinogen in plasma. Complete deglycosylation results in accelerated 
fibrin polymerization, increased lateral aggregation with thicker, less branched fibrin 
fibers and a more porous network (37).
Synthesis of fibrinogen
Fibrinogen in plasma is mainly produced in the liver (38;39) with a half-life in plasma of 
3-5 days (40-42). Synthesis under normal conditions range from 1.7-5 g/day (43). 
Fibrinogen is an acute-phase protein, and during acute-phase conditions such as major 
surgery, bacterial infections and trauma, gene transcription and release of fibrinogen rises 
rapidly. Cytokines in the interleukin-6 (IL-6) family have been recognized as important 
stimulants to increased fibrinogen synthesis. Plasma fibrinogen levels can, thus, increase 
manifold. Fibrinogen and fibrin degradation products (FgDP/FnDP) have been shown to 
stimulate fibrinogen synthesis in vitro (44;45). The results are inconsistent, however, and 
the physiological role of FgDP and FnDP on fibrinogen synthesis in vivo is not clear (44-
48). Although 75% of the total fibrinogen is found in plasma, it may also be found in 
lymph nodes, blood platelets and in interstitial fluid. In vitro studies have shown that 
fibrinogen may also be synthesized by non-hepatic cell lines such as epithelial cells from 
lung and intestine as well as trophoblasts and granulosa cells (49-52). The physiological 
role of this locally produced fibrinogen is not clear. Although the AĮ, Bȕ, and Ȗ chains 
are encoded by dedicated genes closely linked on the distal third of the long arm of 
chromosome 4, bands q23-32 (53),  the transcription of the 3 different genes are closely 
coordinated (54). The gene for the AĮ-chain, located at the centre of the fibrinogen 
cluster, consists of 5 exons that translate into 625 amino acids, 15 of which are removed 
after transcription. The gene coding for the Bȕ-chains contain 8 exons and codes for a 
461 residue polypeptide and the gene coding for Ȗ-chain comprise 10 exons coding for 
the 411 residue Ȗ –chain (53). 
The intracellular assembly of the 3 chains in cytoplasmatic reticulum joins single chains 
to a 3-chained half-molecule which is subsequently joined to the final dimeric fibrinogen 
molecule. When hepatocytes are stimulated with IL-6, the genes for the 3 subunits are 
upregulated simultaneously and to the same extent (55;56). Cytokines such as 
13
interleukin-1ȕ and tumor necrosis factor-Į and glucocorticosteroids may modify the IL-6 
response (54;57).
Variations of the Į-chain 
Heterogeneity in circulating fibrinogen molecules are dominated by heterogeneity of the 
C-terminal Į-chain (58;59). Depending on the degree of C-terminal Į-chain degradation, 
3 main fibrinogen fractions have been described: High molecular weight (HMW-) 
fibrinogen (MW 340 kDa) having both its Į-chains intact; low molecular weight (LMW-) 
fibrinogen (305 kDa), which has lost the C-terminal end of one Į-chain, and very low 
molecular weight (LMW`-)  fibrinogen (280 kDa), which has lost the C-terminal end of 
both Į-chains (2;60). These fractions constitute approximately 70%, 25% and 5%, 
respectively, of the total plasma fibrinogen content. Experiments using western-blotting 
and immunostaining techniques have, however, revealed a considerable larger diversity 
of  AĮ-chain remnants with intact N-terminal ends and MW 66,200 to 36,000 Da in 
normal plasma (61). High molecular weight fibrinogen has lower solubility, shorter 
thrombin clotting time and increased clottability compared to the low molecular forms, 
illustrating the importance of the carboxy- terminal Į-chain for the clotting properties of 
fibrinogen (62-68). Furthermore, clots from ĮC-degraded fibrinogen have decreased 
turbidity and lack mechanical strength compared to native fibrin clots. Although not 
essential for clot formation, the loss of one or both ĮC-terminals significantly retards the 
polymerization process (29;69). In 1992 an extended version of the Į-chain, ĮE, was 
described (70;71). Based on predicted mass, fibrinogen molecules containing the 236 
residue extended Į-chains are called Fibrinogen 420 (MW 420 kDa), to distinguish it 
from the more predominant Fibrinogen 340. Fibrinogen 420 comprises approximately 1 
% of  the total fibrinogen concentration in adults (72). It has been shown to be involved 
in leukocyte adhesion and migration through binding of the ĮEC terminal to the leukocyte 
integrins ĮMȕ2 and ĮXȕ2 (73). 
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Variations of the Ȗ –chain 
Alternative processing of the Ȗ-chain gene transcript gives rise to an alternative Ȗ-chain,
Ȗ`, with a negatively charged 20 amino acid extension at the C terminal end of the Ȗ-
chain, substituting the Ȗ 408–411 with a 20 amino acid sequence, Ȗ`408–427, that 
contains two sulfated tyrosines. The Ȗ`-chain constitutes about 8% of the Ȗ chains (74-
76), and in plasma 10-15% of the fibrinogen molecules contain the Ȗ` variant (77). The 
Ȗ`-chain includes binding sites for thrombin and the B chain of factor XIII, suggesting 
that the Ȗ`-chain function as a carrier for factor XIII in the circulation, making it readily 
accessible during fibrin formation (78).  The Ȗ- and Ȗ`-chains are equally effective cross 
linked by XIIIa. Due to lack of the full platelet binding sequence 400-411, the Ȗ`-chain
does not support ADP induced fibrinogen mediated platelet aggregation (79;80). 
Conversion of fibrinogen to fibrin 
The conversion of soluble fibrinogen to an insoluble fibrin network is initiated by the 
thrombin mediated removal of the fibrinopeptides A and B from the N-terminal AĮ- and 
Bȕ-chains (81). The cleavage of FPA at amino acids 15-16 occurs more rapidly than the 
split of FPB between amino acids 16-17 (82), which has been suggested to be involved in 
lateral growth and branching of the fibrin polymer (83). Thus, 2 FPA and 2 FPB are 
released from each fibrinogen molecule exposing the peptide sequence Gly-His-Arg-Pro-
amide in the Į-knob, and the Gly-Pro-Arg-Pro-amide from the ȕ-knob. Complimentary 
“holes” are located in the globular C-terminal E- and J-chains. Although structurally 
similar, the ȕC- and ȖC-holes are able to distinguish between these peptides. 
Thrombin
Thrombin is a serine protease produced in the liver as the 70 kD zymogene prothrombin 
(84). The 579 residue prothrombin undergoes posttranscriptional modifications before it 
is secreted into the circulation. Following damage to the blood vessel and exposition of 
subendothelial tissue factor (TF), factor X is converted to Xa in the presence of FVIIa 
and Ca2+ in the initial phase of coagulation. Prothrombin is subsequently converted to the 
35 kDa biologically active thrombin by the prothrombinase complex, including FVa, 
FXa, and anionic phospholipids in the presence of Ca2+. Thus, prothrombin is cleaved 
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after Arg320 forming the intermediate mezothrombin and subsequently after Arg271 to 
form thrombin (85). Thrombin comprises a 49 residue light chain and a 259 residue 
heavy chain linked together by a single disulphide bridge. The heavy chain is intra-
connected through 3 disulphide bonds. The initial small amounts of thrombin formed by 
the extrinsic pathway trigger the intrinsic coagulation pathway through activation of FXI, 
FVIII and FV, thus, creating more thrombin.  
The activity half-life of thrombin is only 14 seconds, and it is rapidly inactivated by 
inhibitors. The principal circulating thrombin inhibitors are antithrombin, heparin 
cofactor II (HCII) and protease nexin 1 (86;87). However, thrombin also has the ability to 
inhibit its own generation through interaction with endothelial bound thrombomodulin, 
which activates the protein C pathway.  Protein C and protein S effectively inhibit factors 
Va and VIIIa, thus preventing further thrombin generation. The proteolytic properties of 
thrombin are affected through interaction with Na+. Several Na+ binding sites have been 
identified, the principal binding sites being confined to the C-terminal region of the heavy 
chain (88;89). Binding of Na+ to thrombin alters the protein structure and allosterically 
enhances its catalytic properties. At physiological Na+ concentrations, the sodium binding 
sites in thrombin are fully occupied.  
Polymerization
The removal of the acidic FPA from fibrinogen changes the N-terminal net charge, and is 
followed by a spontaneous polymerization step in which two fibrin monomers (des-AA 
fibrin) are arranged in a non-covalent bonded staggered overlap between the E-domain 
and complimentary binding sites in the C-terminal Ȗ-chain of the D-domain (90). In 
addition to the E-/D-domain interaction, D/D-domain intermolecular bonds form in the 
fibrin oligomer, thus forming a double stranded protofibril. The release of fibrinopeptide 
B, although starting at the same time as the release of FPA, occurs at a slower rate than 
the release of FPA (82;91).  Fibrin gel formation, however, accelerates the FPB release 
rate about sevenfold (92;93). The removal of FPB exposes an additional polymerization 
site in the E-domain called B “knobs” which are complementary to b “holes” in the C-
terminal ȕ-chain (94;95). Removal of the two FPBs induces a conformational change of 
the Į-chain. The two Į-chains, usually stretching parallel to the coiled coil and meeting in 
16
the central E-domain, dissociate and form a mobile extension from the D-domain. This 
allows interaction between neighboring Į-chains, which promotes lateral aggregation of 
fibrin protofibrils and strengthening of the mechanical properties of the clots (96). The 
non-covalent ligation between the E-/D-domains are easily broken by solvents such as 
urea, acetic acid and sodium bromide. Active “knobs” in fibrin monomers or fibrin 
protofibrils may bind to always exposed “holes” in circulating fibrinogen forming soluble 
fibrinogen-fibrin complexes (97;98), thus, inhibiting fibrin polymerization. Even 
degradation products of fibrin and fibrinogen may interact with “holes” in the D-domain 
and affect clot formation 
The fibrin clot architecture is influenced by several factors. High fibrinogen levels and 
fast activation leads to thin fibrin fibers and more rigid clots with smaller pores, making it 
less susceptible to fibrinolytics. Slow activation, on the other hand, leads to thicker fibrin 
strands with larger pores (99).  Ionic strength, increased glucose or homocysteine levels, 
the presence of other plasma proteins (100) and cross linking of proteins such as PAI-2, 
TAFI, Į-2 antiplasmin as well as fibrinogen- and factor XIII-polymorphisms may all 
affect the fibrin clot structure (for review see (101)). 
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Figure 3. Illustration of the conversion of fibrinogen to fibrin by thrombin, fibrin 
polymerization and factor XIIIa mediated cross-linking according to Weisel (22).   
Cross-linking 
The fibrin matrix formed by the action of thrombin is fragile. Through factor XIIIa 
mediated cross-linking of the Ȗ-chains the fibrin clot is strengthened and made resistant to 
physical stress and proteolytic attacks. Factor XIII in plasma is a 326 kDa tetramer 
including 2 A chains and 2 B chains. About half of the total factor XIII in blood is 
contained in platelets in the form of A2 dimers. In plasma, most of the factor XIII 
zymogen A2B2 is bound to fibrinogen, especially to the Ȗ`-chain of Fibrinogen 420 
(102). Factor XIII is activated through the thrombin mediated proteolysis of the A chain. 
Activated factor XIII  induces inter-chain covalent cross-linking between one C-terminal 
glutamine (ȖGln398/399) and one lysine (ȖLys406) residue in adjacent J-chains 
(103;104).  Due to the close proximity of the acceptor and donor sites in the fibrin clot, 
18
factor XIIIa catalyses cross-linking of fibrin much faster than cross-linking of fibrinogen 
(105). Intermolecular Į-chain cross-linking generating Į-oligomers and polymers occur at 
a slower rate and facilitate lateral fibril association and fiber growth. Crosslinking may 
also occur between fibrin Į- and Ȗ-chains, and even between fibrinogen Ȗ-chains.
Metabolism of fibrinogen and fibrin 
Only 2-3% of the fibrinogen molecules are removed from the circulation as a 
consequence of coagulation and subsequent fibrinolysis (106). Although plasmin 
mediated proteolysis is the dominating fibrin degradation pathway, plasmin does not play 
an important role in the degradation of fibrinogen, except during exogenous treatment 
with plasminogen activators (107;108). Furthermore, it seems that HMW-fibrinogen only 
partially is metabolized to LMW-fibrinogen in vivo (108-110). To what extent HMW-
fibrinogen is metabolized to LMW`-fibrinogen, and which additional mechanisms are 
involved in the degradation of fibrinogen in vivo are not clear. 
In vitro studies have shown that the AĮ-, Bȕ-, and Ȗ-chains differ in their susceptibility to 
plasmin (111). The AĮ-chain, with its elongated C-terminal end, is more vulnerable to 
plasmin attacks than the Bȕ- and Ȗ-chains. Similarly, the Bȕ-chains are more susceptible 
to plasmin degradation than the Ȗ-chains. The destruction of the ĮC-domain results in the 
formation of fragment X (MW 250 kDa) and degradation products from the Į-chain
named A, B and C (111;112). Further digestion of the coiled-coil of the fragment X, 
gives rise to fragments D (MW 83-100 kDa) and Y (155 kDa). Fragment Y is quickly 
degraded to the terminal fragments D (81 kDa) and E (41 kDa) (figure 4). Fragment E 
corresponds to the N-terminal domain of the native fibrinogen molecule. Fragments D 
and E constitute the final plasmin mediated fibrinogen degradation products. The affinity 
of plasminogen to polymerizing fibrin is stronger than to circulating fibrinogen. Although 
fibrinogen has high affinity binding sites for plasminogen at the C-terminal Į-chain, the 
formation of the ternary complex fibrin-plasminogen-t-PA is required to accomplish 
effective t-PA mediated plasminogen activation. The fibrinolysis of cross-linked fibrin 
creates distinct degradation products such as D-D (D-dimer), comprising two fragments 
D joined by Ȗ-Ȗ cross-links (113;114), and the non-covalent combination of fragment D-
D with fragment E (115). Further degradation of D-dimer, and digestion of the C-
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terminal end of the AĮ-chain by human neutrophil elastase has been shown in vitro 
(64;116).
Figure 4. Illustration of the plasmin mediated degradation of fibrinogen to the 
intermediary X and Y molecules, and the final degradation products D and E. 
Reproduced from Gaffney (113). 
Fibrinogen and risk of cardiovascular disease  
A number of clinical trials have shown an association between high fibrinogen levels and 
increased risk of cardiovascular disease (11;117-120). In a metaanalysis comprising 18 
prospective studies and 4000 patients with coronary heart disease (CHD), the relative risk 
of CHD was 1.8 (95 % confidence interval 1.6-2.0) in patients with fibrinogen 
concentration in the highest tertile compared to the lowest (121). Increased plasma 
fibrinogen concentrations have also been related to adverse  prognosis following  
myocardial infarction (122;123), increased risk of stroke (124) and increased 
cardiovascular- and total mortality in asymptomatic patients (118). The observation that 
fibrinogen is a strong and independent marker for CHD has raised the question whether 
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high fibrinogen levels promote the atherothrombotic process, or is only a marker of the 
chronic low-grade inflammation associated with atherosclerotic vascular disease (125). 
Possible mechanisms by which fibrinogen may increase CHD risk include its 
contribution to plasma- (126) and blood viscosity (127;128). Furthermore, a high 
fibrinogen concentration has been shown to correlate with increased size, weight, and 
fibrin content of thrombi (129).  The key role of fibrinogen in platelet aggregation, and its 
modulating effect on endothelial function and smooth muscle proliferation, might also 
affect the atherothrombotic process. On the other hand, studies using genetically 
modified mice have indicated that fibrinogen is not strictly required for the development 
of advanced atherosclerotic disease (130).
Fibrinogen and plasma viscosity 
Viscosity (Ș) can be defined as a fluid’s resistance to flow attributable to internal friction 
between molecules or larger particles (131). Isaac Newton (1642-1727) described a 
model for the viscous properties of fluids, suggesting that the viscosity is proportional to 
the velocity at which parts of the fluid are separated from one another due to the flow. 
Newtonian fluids flow like water, and is characterized by changes in its shear rate being 
proportional equal to changes in shear stress (Ȗ = V/H where V is the velocity and H is 
the distance between two parallel plates). Shear stress is the applied force per unit area 
which causes relative movement of fluid layers, and can be described by the equation:  
  (Ĳ= the shear stress exerted by the fluid, ȝ=the fluid viscosity, dv/dx=the
velocity gradient perpendicular to the direction of shear). In non-newtonian fluids, 
however, the viscosity changes inversely with the shear rate. This implies that for a 
Newtonian fluid such as plasma, viscosity depends only on pressure, temperature and the 
chemical composition of the fluid. Different principles have been utilized to determine 
the viscosity of blood and plasma (132). The “falling-ball” viscometer provides an easy 
and precise method of measuring the viscosity of Newtonian, low-viscosity fluids such as 
plasma. By measuring the time taken by a solid sphere to travel a given distance through 
an inclined glass tube filled with the sample, the viscosity can be calculated. 
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Albumin, globulins (alpha-1, alpha-2, beta and gamma globulins) and clotting factors 
constitute the main proteins in plasma. In addition to plasma concentration, the size and 
shape of proteins determine the effect on plasma viscosity (133). The fibrinogen 
molecule is a large, rod shaped protein, and fibrinogen has been shown to be a major 
determinant of plasma viscosity. Variations in plasma viscosity between subjects can 
partly be attributed to variations in plasma fibrinogen levels (134;135).  
Fibrinogen and acute-phase 
The initial host response to tissue injury such as infections, major surgery, trauma and 
some malignant conditions comprises a series of predetermined, coordinated events. This 
early immune response, called the “acute-phase reaction” (APR), is initiated by the 
recognition by specific cell receptors of microbial antigens such as lipopolysaccarides 
(LPS) or other components of the bacterial cell wall (136). The APR includes a local and 
a systemic response characterized by fever, leukocytosis and increased metabolic rate. In 
the micro vasculature changes in vascular permeability is observed. Important cytokines 
involved in the amplification and propagation of the APR include IL-1ȕ, TNF-Į, IL-6 and 
IFN-Ȗ (137). Animal studies have indicated a critical role of IL-6 on upregulation of the 
synthesis and release of acute phase proteins such as clotting-, and complement factors, 
immune modulating proteins such as fibronectin, CRP, amyloid A and proteins such as 
haptoglobin, ferritin, ceruloplasmin and Į1-antitrypsin (137;138). The increased mRNA 
transcription of the different acute phase proteins is mediated through activation of 
various nuclear factors (139;140). Plasma fibrinogen concentration may increase 2 to 10 
fold during acute phase conditions. Holm and colleagues showed that the increased 
fibrinogen concentration was mainly due to increased levels of HMW-fibrinogen, with a 
modest increase in LMW-fibrinogen (2). Due to the increase in HMW-fibrinogen 
synthesis, the HMW-/LMW-fibrinogen ratio raises 4-8 hours following the initiation of 
the acute phase, reaching its highest level after 3-4 days (2). The elevated HMW-/LMW-
fibrinogen ratio gradually returns to normal levels during the ensuing week, whereas total 
fibrinogen levels may remain elevated for a longer period of time (2). HMW-fibrinogen 
has been shown to have increased clotting rate as reflected by shorter thrombin clotting 
time compared to LMW-, and LMW`-fibrinogen (63). The degree of phosphorylation of  
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fibrinopeptide A has been shown to increase from 25-30% in normal plasma to more than 
50% during acute phase conditions (141). 
Fibrinolysis
Activation of coagulation at sites of vascular damage is vital to prevent fatal blood loss.
Confining the coagulation process to the place of injury and the subsequent lysis of the 
clot are, however, equally important to prevent excessive thrombosis and maintain 
patency of the vasculature. The fibrinolytic system comprises the proenzyme 
plasminogen, which is converted to the active enzyme plasmin by tissue type 
plasminogen activator (t-PA) or urokinase type plasminogen activator (u-PA). Plasmin 
cleaves the fibrin(ogen) molecule at multiple sites resulting in the formation of 
fibrin(ogen) degradation products (FgDP and FnDP).
Plasminogen
Plasminogen is a single-chain glycoprotein found in plasma at 1.5-2.0 ȝM concentrations. 
The molecule comprises 791 amino acids with MW 92 kDa, including 5 homologous 
triple-loop structures of  MW 10 kDa each (142). The interaction of plasmin with fibrin 
and Į2-antiplasmin is mediated by lysine- and aminohexyl binding sites located in the 
triple-loops.  In addition to the native glu-plasminogen, limited plasmic digestion results 
in modified forms, lys-plasminogen, containing N-terminal lysine, valine or methionine 
(143). Through cleavage of the Arg561-Val562 peptide bond plasminogen is converted to 
the active two-chain serine protease plasmin (144). Plasmin is the natural protease for the 
dissolution of fibrin in vivo. 
Plasminogen activators 
Tissue type plasminogen activator (t-PA) is a 527 residue serine protease with MW 70 
kDa. Hydrolysis of the Arg275–Ile276 bond converts it to a two chained form, 
interconnected by a disulfide bond (145). It is released from the vascular endothelium 
into the vessel lumen as a result of stress, exercise, venous occlusion and specific drugs 
(146). Circulating t-PA is mostly bound to plasminogen activator inhibitors (PAI) (147). 
Residues 276-527 constitute the serine protease domain with the active site amino acids 
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His 322, Asp371 and Ser478 (148). t-PA activity is greatly enhanced by the presence of 
fibrin,  and is further amplified through the subsequent formation of  fragment-X through 
plasmin mediated splitting of the C terminal Į-chain and N-terminal of the ȕ–chain of 
fibrin (149). In vitro studies suggest that the plasminogen activating capacity of the 3 
natural occurring principal fibrin subfractions with different degree of Į-C degradation 
does not differ (150). Kinetic in vitro studies on the activation of plasminogen in the 
presence of fibrin(ogen) suggest that t-PA adheres to the fibrin surface with subsequent 
addition of plasminogen to form a cyclic ternary complex, thus preventing the activation 
of circulating plasminogen (151). The plasmin formed on the fibrin surface is not readily 
inactivated by circulating Į2-antiplasmin (half-life 10-100 seconds). Circulating plasmin, 
on the other hand, has a half-life of only 0.1 seconds (152). 
Urokinase-type plasminogen activator (u-PA) 
u-PA is synthesized as a single chain (scu-PA) pro-urokinase, which is converted to the 
active two-chained urokinase-type plasminogen activator (tcu-PA) by plasmin. Even 
enzymes such as kallikrein, trypsin, cathepsin B, human T cell associated serine 
proteinase-1, and thermolysin may catalyze the proteolysis of scu-PA. tcu-PA is a 411 
residue serine protease with MW 55 kDa containing the active site triad His204 , Asp255 , 
and Ser356. The plasminogen activating potential of scu-PA is small compared with tcu-
PA. However, the modest plasmin quantity generated by scu-PA is sufficient to stimulate 
further plasminogen activation by converting scu-PA to the active tcu-PA  (153;154). 
Ligation of u-PA to its cell-surface receptor (u-PAR) found in a variety of cells, is 
important for its activity. Plasmin generated from receptor bound u-PA plays a central 
role in the mediation of pericellular proteolysis, and is protected from rapid inactivation 
by its principal circulating inhibitor Į2-antiplasmin (155). 
Inhibition of fibrinolysis 
Į2-antiplasmin 
Į2-antiplasmin is the principal inhibitor of human plasmin (156). The 464 residue serpine 
is a glycoprotein with MW 67 kDa, and the plasma concentration is approximately 1 mM. 
The 464 residue Į2-antiplasmin and a shorter form containing 453 amino acids are 
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present in plasma in about equal concentrations, and both form stable complexes with 
plasmin (157). Through interaction with the Į2-antiplasmin reactive site located at 
Arg376-Met377 plasmin forms a 1:1 stochiometric inactive complex (158). Plasmin not 
neutralized by Į2-antiplasmin may be inactivated by circulating Į2-macroglubuline 
(159).
Plasminogen activator inhibitor 
In addition to inhibition of plasmin, fibrinolysis may also be inhibited at the activator 
level by plasminogen activator inhibitor 1 (PAI-1). It is a single chain, 379 residue 
glycoprotein with MW 52 kDA belonging to the serpine family (160;161). The active site 
is located at Arg346-Met347. PAI-1 becomes activated through interaction with 
vitronectin. This interaction induces a conformational change and an elongation of the 
reactive center loop (RCL) of the molecule, thus enabling the active binding site for 
plasminogen activators (162). Active PAI-1 rapidly interacts with one- and two-chained 
t-PA and two-chained u-PA, thus efficiently preventing fibrinolysis. In addition to its 
principal role as inhibitor of activators of fibrinolysis, PAI-1 has been shown to 
participate in angiogenesis.
Thrombin-Activatable Fibrinolysis Inhibitor 
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a single chain protein in the family 
of zinc containing metallocarboxypeptidases with MW 60 kDa. It is produced in the liver 
in its inactive form, TAFI, and found in plasma at a concentration of 75 nM. Following 
activation by thrombin, plasmin or trypsin, the active form, TAFIa, exerts it 
antifibrinolytic effect by cleaving off C-terminal lysine residues from partially degraded 
fibrin. The lysine residues stimulate t-PA mediated plasmin activation. TAFIa, thus, 
prevents additional binding of plasminogen to the clot and inhibits further fibrinolysis 
(163;164).
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Fibrinogen assays 
Different techniques have been employed to determine the fibrinogen concentration in 
plasma. The method described by Jacobsson in 1955 has often been regarded as a 
reference method, reflecting the total clottability of fibrinogen (165). The fibrinogen 
concentration is measured after adding thrombin to a buffer diluted plasma sample, 
leaving the sample to clot for 2 hours, with subsequent syneresis and washing of the clot, 
and measuring the total clottable protein content spectrophotometrically after dissolving 
the clot in urea. The method is laborious and time consuming, and is not easily 
automated. Thus, it is not commonly used as a routine method. An assay based on the 
clotting rate of a diluted plasma sample was described by Clauss in 1957 (166), and 
implies the addition of a large quantity of thrombin to a diluted plasma sample, and 
recording the time to clot formation. Due to the high thrombin concentration, fibrin 
monomers form rapidly, and the method reflects the fibrinogen concentration and the 
polymerization properties of the fibrin monomers. The coagulation endpoint can be 
assessed manually as elapsed time to the formation of a visual clot, but clotting rate 
assays are also easily automated, making them suitable for routine purposes. 
Other methods, such as salt or heat precipitation (167-169), are less commonly used as 
routine assays. Immunochemical assays are based on polyclonal antibodies reacting with 
epitopes on the fibrinogen molecule (167;170). The light scatter of insoluble antigen-
antibody complexes correlates to the fibrinogen concentration in the sample. Other 
immunological methods include fibrinogen quantification using ELISA techniques. The 
variety of methods used to determine plasma fibrinogen levels, in addition to 
heterogeneous calibration standards, have made comparison of fibrinogen levels obtained 
from different laboratories difficult (171). In order to obtain comparable estimates of 
fibrinogen concentrations, the First International Fibrinogen Standard (IS) (89/644) was 
introduced by the National Institute for Biological Standards in 1992 (172), and replaced 
in 2000 by the 2nd  IS for fibrinogen (173). The freeze-dried calibration plasma has 
enabled laboratories and manufacturers to calibrate against a common international 
fibrinogen standard.
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Fibrinogen interaction with blood platelets and leukocytes  
Through interaction with specific cell surface integrin receptors, fibrinogen may interact 
with blood platelets and leucocytes. Integrins are transmembrane, heterodimeric 
glycoprotein receptors, and their main tasks include coordination of cell adhesion to extra 
cellular matrix and cell to cell interactions (174). After activation by agonists such as 
ADP, collagen or thrombin the platelets become activated and display the GP IIb/IIIa 
integrin (Į2bȕ3), allowing fibrinogen-platelet interaction. Fibrinogen is the predominant 
ligand for activated platelets at low shear rates, whereas vWF is the physiologically 
important ligand at high share rates (175;176). The platelet-fibrinogen interaction is 
closely regulated to prevent spontaneous intravascular aggregation with potential 
deleterious effects. The IIb/IIIa receptor, therefore, is not constitutively expressed on 
platelets. Although both the fibrinogen Į-chain Arg-Gly-Asp (RGD)-sequences (AĮ 95-
97 and 572-574) and the C terminal Ȗ-chain (Ȗ 400-411) are potential ligands for GP 
IIb/IIIa, fibrinogen-dependent platelet aggregation requires an intact C-terminal Ȗ-chain.
Thus, the alternatively spliced Ȗ-chain, Ȗ`, does not support platelet aggregation (177). 
The Į-chain RGD sequences are neither necessary nor sufficient for platelet aggregation 
(178). Fibrinogen may also interact with the leukocyte integrin ĮMȕ2 (CD11b/CD18, 
Mac-1). The fibrinogen J- chain region (Ȗ 377-395 and Ȗ 190-202) functions as ligands 
for the leukocyte ĮMȕ2 in vivo (179;180). Thus, fibrinogen binds to activated leucocytes, 
in the presence of divalent cations, with the association of about 150 000 fibrinogen 
molecules per cell (181). Previous studies have shown that fibrin(ogen) may have 
different effects on leukocyte function (182-184), and fibrin is involved in monocyte 
adhesion to endothelium and migration at sites of inflammation (185;186). Furthermore, 
fibrinogen plays an important role in the inflammatory response to implanted 
biomaterials (187;188). In addition to platelets and leucocytes, fibrinogen may also 
interact with fibroblasts, endothelial- and, epithelial cells (189;190). 
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5. AIMS OF THE STUDY 
x To investigate the effect of freeze-drying on the clotting properties of fibrinogen, 
and how the use of a freeze-dried calibration standard might affect the results of a 
commonly used clotting rate fibrinogen assay. 
x To determine whether the fibrinogen concentrations obtained by a clotting rate 
assay deviated from levels found using a method based on total clottability during 
acute-phase conditions, and to investigate if a discrepancy between the two 
methods correlates with changes in the HMW-fibrinogen fraction. 
x To determine the influence of the major fibrinogen subfractions on the viscosity 
of native fibrinogen, and investigate the effect of EDTA on the viscosity of 
purified fibrinogen and plasma. 
x To study the effects of moderate red wine consumption on plasma viscosity, 
fibrinogen concentration, and the distribution of the 3 major fibrinogen 
subfractions.
x To investigate potential proinflammatory effects of purified fibrinogen and fibrin 
on isolated peripheral blood mononuclear cells (PBMC) as reflected by increased 
mRNA expression and synthesis of the proinflammatory cytokines IL-6, TNF-Į
and IL-1ȕ, and to assess the significance of an altered HMW/LMW-fibrinogen 
ratio.
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6. MATERIALS AND METHODS
Study subjects 
In paper I blood samples drawn from 14 healthy subjects (7 men, 7 women, and median 
age 22) were used to determine the fibrinogen concentrations in plasma before and after 
freeze-drying. Blood samples for the preparation of fresh-frozen and freeze-dried 
calibration standards were collected from 20 healthy subjects (10 men, 10 women, 
median age 22). The fibrinogen concentration in blood samples from 30 apparently 
healthy subjects (15 men, 15 women, median age 24) and 10 patients undergoing major 
elective surgery (4 men, 6 women, median age 66) were used to determine any 
discrepancy in fibrinogen concentration using the fresh frozen calibration standard 
compared to the freeze-dried standard. 
In paper II the fibrinogen concentrations and the distribution of fibrinogen subfractions in 
7 patients about to undergo elective surgery were studied (4 men, 3 women, median age 
66 years). Three patients were undergoing total hip joint replacement, 2 had an 
explorative laparotomy, and 2 patients were undergoing hemicolectomy.  
In paper IV we studied the effect of moderate red wine on fibrinogen levels, the 
distribution of fibrinogen subfractions and plasma viscosity in 92 healthy, nonsmoking 
men (35%) and women (65%) (mean age 50.3 years). Baseline characteristics of the 
study population are specified in paper IV. 
In paper V we studied the effect of purified fibrinogen and HMW-fibrinogen on the 
synthesis of proinflammatory cytokines from isolated PBMC collected from 9 healthy 
subjects (5 women, 4 men, median age 31 years). 
Fibrinogen assays 
Total clottable protein assay 
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The total clottable protein assay was performed according to a modification of the 
method described by Jacobsson (165). Plasma was diluted to one fourth of its original 
concentration by adding phosphate buffer and thrombin (final concentration 7.5 NIH 
U/ml). After clotting for 30 min, the clot was synerized, washed in 0.9% saline and 
dissolved in 40% alkaline urea. The fibrinogen concentration was then calculated by 
measuring the absorption at 280 nm using the clot solvent as a blank, and correcting for 
extraneous absorption at 320 nm and 360 nm. The intra-assay coefficients of variation 
were 1.5% at a fibrinogen concentration of 3.6 g/l (n = 10) and 1.6% at a concentration of 
4.7 g/l (n = 10). 
Clotting rate assay
Fibrinogen concentrations in the experiments presented in paper II and III were 
determined using a clotting rate assay as described by Clauss (191). 200 ml of a solution 
containing 1 volume citrated plasma and 9 volumes sodium barbital buffer were 
incubated at 37 °C for 2 minutes. 100 μl thrombin 100 NIH U/ml was added, and the 
clotting time was determined. If the clotting time was shorter than 7 seconds, a higher 
dilution of plasma was used. If the clotting time exceeded 15 seconds, a lower plasma-
dilution was used.
Automated clotting rate assay
Fibrinogen concentrations in the studies presented in paper I and IV were determined by 
and automated clotting-rate assay (Automated Coagulation Laboratory Futura®, 
Instrumentation Laboratory, Lexington, MA, USA) using the principle of turbidimetric 
clot detection. The intra-assay CV for the clotting-rate assay was 3.2% (n=10) 
Freeze-drying
Freeze-drying of plasma samples (1 ml in each sample) was performed by The Axis-
Shield company (Oslo, Norway), based on international guidelines (192), using a 
Gambolt GT 150 freeze dryer. The samples were sealed under vacuum, stored in small 
glass ampoules at -20 °C and reconstituted by adding 1 ml of purified water before use. 
Residual humidity in freeze-dried plasma samples was 0.4–0.6%. 
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Thrombin clotting time 
0.1 ml of 3 IU/ml thrombin was added to 0.2 ml plasma or fibrinogen solution, incubated 
at 37 °C and the clotting time recorded.  
Electrophoresis
Gels (3% polyacrylamid and 0.5% agarose) were prepared as described by Weinstein and 
Deykin (193). The electrophoretic procedure was performed using a Mini-PROTEAN® 
II (BioRad, Richmond, CA, USA). The gels were Coomassie-stained, and the fibrinogen 
fractions quantified by densitometric scanning using Kodak image station 440 CF with 
Kodak 1D image analysis software. The intra-assay coefficient of variation for the 
electrophoresis and densitometric scanning was 1.8% (n =10). 
Fibrinogen purification  
Fibrinogen used in paper III was purified from plasma donated by healthy volunteers 
using the ȕ-alanine precipitation method described by Jacobsen and Kierulf (194), except 
that citrate (final concentration 0.011 M) was present during the entire procedure. 
Trasylol (final concentration 200 KIU/ml) and soybean trypsin inhibitor (STI, final 
concentration 0.1 mg/ml) were used as inhibitors instead of Epsilon aminocaproid acid.  
Separation of HMW-, LMW- and LMW`-fibrinogen
Separation of the fibrinogen fractions was performed by gradual precipitation of a 
purified fibrinogen solution. A saturated ammonium sulphate solution was added slowly 
during constant stirring. The HMW-fraction was prepared by the addition of saturated 
ammonium sulphate to 19% saturation. After centrifugation at 1200 g for 7 min the 
precipitate was collected, dissolved in 0.15 M NaCl at 37 °C, re-precipitated in 
ammonium sulphate (19%), leaving the precipitate to dissolve in 1/3 of its original 
volume and finally dialyzed. The LMW-fraction was obtained from precipitate formed at 
22–24% ammonium sulphate saturation and the LMW`-fraction at 26–30% saturation. 
Precipitates were centrifuged, dissolved in 0.15 M NaCl at 37 °C and dialyzed. All 
fractions were dialyzed three times against 500 vol diemal buffered saline for 24 h. 
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Contamination with soluble fibrin and other low solubility complexes were removed by 
leaving the dialyzed fractions at + 4 °C for 24 hours and removing insoluble material 
after centrifugation. The purity of the fibrinogen fractions was determined by sodium 
dodecyl sulphate (SDS) gel electrophoresis. The HMW-fibrinogen fraction was 
contaminated with 1% LMW. The LMW-fraction contained 96% LMW- and 4% LMW`-
fibrinogen, and the LMW`-fraction contained 90% LMW`-fibrinogen and 10% HMW- 
and LMW-fibrinogen. The thrombin clotting times were 15, 24 and 31 seconds for 
HMW-, LMW- and LMW`-fibrinogen, respectively. The clottability of HMW-fibrinogen 
was 100%, of LMW-96% and of LMW`-fibrinogen 76%. 
Viscometry  
The viscosity of fresh plasma, purified fibrinogen and fibrinogen subfractions were 
determined using Haake Microvisco® 2 viscometer (Haake Mess-Technik, Munich, 
Germany). A metal sphere of standard weight and size was inserted into a precision cut 
syringe containing the sample, and placed in a tilted position inside the viscometer 
containing two photo sensors. The time needed by the ball to pass between the two photo 
sensors was measured and the viscosity calculated. The intra-assay coefficient of 
variation for the viscometer was 0.4% (n=10).  
Isolation of PBMC 
Whole blood was drawn by clean venipuncture from healthy volunteers who had not used 
any medication two weeks prior to inclusion, and collected into lipopolysaccharide 
(LPS)-free Vacutainer® tubes (Cedex, France) containing 7 mM EDTA. PBMC were 
isolated from whole blood under sterile conditions using Lymphoprep® (Axis-Shield PoC 
, Norton, MA, USA). Cell cultures comprised 81% lymphocytes, (25, 75 percentiles: 69, 
82%), 11% monocytes (11, 14%) and 8% granulocytes (7, 16%). 
RNA isolation and mRNA quantification 
PBMC were incubated with purified HMW- or unfractioned fibrinogen (final 
concentration 0.2 mg/ml or 0.5 mg/ml) and RPMI-1640 containing 25 mM HEPES and 
L-glutamine. Following centrifugation the cell pellets were lysed in 250 ȝl lysis/binding 
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buffer (MagNA Pure LC RNA Isolation Kit-High Performance) and stored at –70 °C 
until analyzed. Total RNA was isolated using a MagNA Pure robot (Roche Diagnostics, 
Basel, Switzerland) and the “RNA hp-cells” protocol. The amount of total RNA was 
quantified using the NanoDrop® spectrophotometer (NanoDrop technologies, 
Wilmington, DE, USA) as described in paper V. Detection of the relative change in gene 
expression in fibrinogen stimulated PBMC compared to controls normalized to an 
endogenous reference (GAPDH mRNA) was estimated using the Comparative C Method 
of relative quantification (ǻǻCt method) (195). 
Cytokine analysis 
Concentrations of IL-6, TNF-Į and IL-1ȕ were determined in cell-lysate using 
commercial enzyme linked immunosorbent assays (ELISA) from R&D Systems 
(Minneapolis, MN, USA). Measurements were done in duplicates according to the 
manufacturer’s instructions and the mean concentrations were calculated. The intra-assay 
CVs for the IL-6 cytokine assay were 1.7% at low (16.8 pg/ml) and 4.4% at high (191 
pg/ml) concentrations, whereas the inter-assay CVs were 2.0% and 3.7%, respectively. 
Intra-assay CVs for the IL-1ȕ assay were 2.4 at low (12.6 pg/ml) and 3.4% at high (192 
pg/ml) concentrations, and the inter-assay CVs 3.4% and 7.1%, respectively. For the 
TNF-Į assay the intra-assay CVs were 5.3% at low (2.4 pg/ml) and 8.8% at high (14 pg/ 
ml) concentrations, and the inter-assay CVs 10.8% (2.4 pg/ml) and 16.7% (14 pg/ml), 
respectively. 
Statistics 
Normally distributed data were reported as mean ± standard deviation (SD). Comparison 
of data sets were valuated using Student`s t-test, and reported as the mean difference with 
95% confidence interval (paper IV). Correlations between normally distributed variables 
were determined using Pearsons`s method.  
If not normally distributed, data were presented as medians with range or the 25, 75 
percentile. Comparisons between data sets were made using Wilcoxon signed rank test 
(paper I, II, III, V), and correlations between variables performed using Spearman`s rank 
correlation test. P values are two sided, and values less than 0.05 were regarded as 
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statistically significant. Statistical analyses were performed using the Statistical Package 
for Social Sciences version 11.0 and SamplePower 2.0 (SPSS Inc., Chicago, Illinois, 
USA). 
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7.  SUMMARY OF RESULTS
I
Influence of freeze-drying on the clotting properties of fibrinogen in plasma 
In paper I we studied the effect of freeze-drying on the clotting properties of fibrinogen. 
Freeze-dried plasma standards are commonly used to calibrate fibrinogen assays. Altered 
clotting properties following the freeze-drying process might influence the results 
obtained when using clotting rate assays to determine fibrinogen concentrations. To 
evaluate the effect of freeze-drying, we determined the fibrinogen concentrations in 
citrated plasma samples using a total clottable protein method and a clotting rate assay 
before and after freeze-drying. When using the clotting rate assay, significantly higher 
fibrinogen concentrations were found in fresh-frozen plasma samples compared to freeze-
dried samples (P<0.001). In freeze-dried plasma samples, the fibrinogen concentrations 
were significantly higher using the total clottable protein assay than the clotting rate 
assay (P<0.001). When measuring the fibrinogen concentrations in plasma samples with 
a wide range of fibrinogen concentrations using the clotting rate assay, significantly 
higher fibrinogen concentrations were found using the freeze-dried calibration plasma, 
than the fresh-frozen calibration plasma ( P=0.02). The results indicate that the clotting 
rate of fibrinogen in citrated plasma is reduced following freeze-drying. When applying 
freeze-dried calibration plasma in a clotting rate assay, higher fibrinogen concentrations 
are obtained than by using fresh-frozen plasma.  
       II
Discrepancy between fibrinogen concentrations determined by clotting rate and 
clottability assays during the acute-phase reaction 
Little is known about the influence of the acute-phase reaction on clotting rate assays. In 
this paper we wanted to investigate discrepancies between fibrinogen concentrations 
obtained by a clotting rate assay (as described by Clauss) and a total clottable protein 
assay (according to Jacobsson). We compared the fibrinogen concentrations using the 
two methods, and determined the HMW (High Molecular Weight)-, LMW- and LMW`-
fibrinogen fractions in plasma samples collected preoperatively and on postoperative 
days 1, 3, and 5 in patients undergoing major elective surgery. Good agreement between 
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the two assays was found in samples drawn before the operation. In samples collected on 
postoperative days 1 and 3, the fibrinogen concentrations determined by the clotting rate 
assay were significantly higher than the concentrations measured with the total clottable 
protein assay (p = 0.015 on both days). SDS-gel electrophoresis showed an increase in 
the median HMW-fraction from 69.7% (range 64.3-70.4) in preoperative samples to 
85.8% (80.7-87.6) in samples drawn on day 3. The difference between fibrinogen 
concentrations obtained by the two methods was significantly correlated to the HMW-
fraction of the samples (r=0.81, p < 0.0001). 
III
The viscosity of fibrinogen subfractions and of EDTA denatured fibrinogen do not 
differ from that of native fibrinogen 
Fibrinogen is a major determinant of plasma viscosity. It has been suggested that the 
increased risk of cardiovascular disease associated with a high fibrinogen concentration 
may partly be attributed to its effect on viscosity. In paper III we wanted to evaluate how 
the three fibrinogen subfractions high molecular weight (HMW)-, low molecular weight 
(LMW)-, and very low molecular weight (LMW`)-fibrinogen affect viscosity. 
Furthermore, the viscosity of plasma is usually determined in ethylenediaminetetraacetic 
acid (EDTA) anticoagulant plasma samples. EDTA affects the clotting properties of 
fibrinogen due to denaturation, which might also affect the viscosity of fibrinogen. Thus, 
we also wanted to investigate the effects of EDTA on the viscosity of fibrinogen. Purified 
fibrinogen was obtained by beta-alanine precipitation of plasma from healthy donors. 
Separation of the fibrinogen fractions was performed by gradual precipitation of purified 
fibrinogen by ammonium sulphate. The viscosity was determined using a Haake 
Microvisco 2 viscometer. The viscosity of the three fibrinogen subfractions did not differ 
significantly from that of native fibrinogen. A significant prolongation of the thrombin 
clotting time was observed in the fibrinogen solution containing EDTA at 37 °C 
compared to 20 °C. However, the viscosity of EDTA anticoagulated purified fibrinogen 
and plasma samples did not differ from that of heparin anticoagulated samples. 
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IV
A daily glass of red wine induces a prolonged reduction in plasma viscosity: a 
randomized controlled trial. 
Moderate red wine consumption has been linked to reduced risk of coronary heart 
disease. Reduced plasma viscosity and reduced fibrinogen levels have been launched as 
possible contributors to this risk reduction. In study IV we investigated the effect of 
moderate red wine consumption on plasma viscosity, fibrinogen concentration and 
fibrinogen subfractions. We recruited 92 healthy, nonsmoking volunteers to consume one 
glass of red wine daily for 3 weeks in a prospective, randomized cross-over study. In the 
second 3-week period the volunteers abstained from alcohol use. The plasma viscosity, 
fibrinogen concentration and the distribution of the main fibrinogen subfractions were 
determined at inclusion, after wine drinking and after abstention. Plasma viscosity was 
reduced by 0.026 and 0.024 mPa.s in the two groups following wine intake (95% CI 
0.009-0.043, p=0.004/0.0083-0.039, p=0.003). The decrease in plasma viscosity was 
maintained following 3 weeks of abstention. The fibrinogen concentration was reduced 
by 0.17 g/l following wine drinking in the group starting with abstention (CI 0.04-0.29, 
p=0.01). The distribution of the fibrinogen subfractions remained unaltered. The 
decreased viscosity levels were maintained after 3 weeks of abstention, suggesting a 
sustained viscosity lowering effect of red wine. 
V
Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from isolated 
peripheral blood mononuclear cells 
Fibrinogen in plasma includes three main fractions; high-molecular-weight (HMW) -
fibrinogen, low-molecular-weight (LMW) -fibrinogen, and very-low-molecular-weight 
(LMW`) -fibrinogen. During acute-phase conditions, plasma fibrinogen levels and the 
HMW-/LMW-fibrinogen ratio increase rapidly due to increased synthesis of HMW 
fibrinogen. The consequences of elevated plasma fibrinogen levels and local deposition 
of fibrin in inflammatory tissues observed during acute-phase conditions are not clear. 
We wanted to investigate proinflammatory effects of fibrinogen and fibrin on peripheral 
blood mononuclear cells (PBMC) as reflected by altered mRNA expression and synthesis 
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of the proinflammatory cytokines IL-6,TNF- Į and IL-1ȕ , and to explore the significance 
of altered HMW-/LMW-fibrinogen ratio. PBMC were isolated from whole blood using 
Lymphoprep®. HMW-fibrinogen was separated from unfractioned fibrinogen by 
ammonium sulphate precipitation. Cells were incubated with unfractioned fibrinogen, 
HMW-fibrinogen or fibrin. Cytokine levels in cell lysates were determined using ELISA 
assays. Real-time PCR was used for mRNA quantification. We found that fibrinogen 
significantly increased mRNA levels, and induced synthesis of the proinflammatory 
cytokines IL-6 and TNF- Į in PBMC in a dose dependent manner. Median (25, 75 
percentile) IL-6 and TNF- Į concentrations were 12 (5, 40) pg/ ml and 16 (0,61) pg/ml, 
respectively. Median mRNA quantity was increased 12.3– (6.6, 48.6) and 1.7– (1.5, 6.5) 
fold for IL-6 and TNF- Į compared to controls. The stimulatory effect of unfractioned 
fibrinogen was not significantly different from HMW-fibrinogen. Fibrinogen and fibrin 
were equally effective in promoting cytokine synthesis from PBMC.  
8. GENERAL DISCUSSION 
Paper I 
In 1991 the standardization and scientific committee of the International Society on 
Thrombosis and Haemostasis (ISTH) supported the establishment of a lyophilized 
fibrinogen standard (coded 89/644) as an international standard for fibrinogen. The 
lyophilized plasma was manufactured by The National Institute for Biological Standards 
and Control (UK) and comprised lyophilized material from a plasma pool of 25 healthy 
donors (196). The fibrinogen concentration was determined by 22 different laboratories, 
and the declared concentration of 2.4 g/l clottable protein was the geometric mean of the 
reported values from the participating laboratories. A total clottable protein method was 
the recommended assay to determine the fibrinogen concentration in the standard.  The 
use of a common calibration standard is essential to obtain accurate and comparable 
results between laboratories. Previous studies have indicated that the declared value of 
standards in commercial available fibrinogen kits may vary by as much as 200% (197).  
In paper I we investigated the effect of freeze-drying of plasma samples on the fibrinogen 
concentrations obtained by an modified automated Clauss assay compared to a total 
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clottable protein according to Jacobsson (165). The total clottable protein assay yielded 
similar results in fresh frozen and freeze-dried samples. When using the clotting-rate 
assay, however, significantly higher fibrinogen concentrations were found in fresh-frozen 
samples compared to those found in freeze-dried specimens (mean difference 0.18 g/l, 
95% confidence interval 0.13– 0.23, P < 0.001). The precision of both fibrinogen assays 
were evaluated, and given as the percent coefficient of variation (CV). The intra-assay 
CVs of the fibrinogen assays used were less than 2 % at the fibrinogen concentrations 
found in our samples, which indicate a high precision. Although inter-assay CVs were 
not determined, between-days variability was reduced by performing all comparisons 
between the two assays on the same day and by the same operator.  Freeze-drying has 
been suggested to induce changes in the secondary and tertiary structure of proteins 
(198;199). This denaturation might affect its physical properties and biological activity. 
As the principal function of fibrinogen is clotting, the freeze drying process may inflict 
conformational changes in the native structure which might affect its clotting properties. 
Reduced clottability has been considered as evidence of denaturation of fibrinogen. Ly 
and coworkers suggested, however, that the thrombin clotting time might be a better 
indicator of denaturation than the clottability (200). They also found that the denaturation 
process did not reduce the fibrinogen N-terminal susceptibility to thrombin. This may 
imply that denaturation primarily affects the polymerization properties of the fibrin 
monomers, thus, influencing assays based on clotting rate to a larger extent than assays 
reflecting the total clottability of fibrinogen. The use of diluted plasma and large amounts 
of thrombin in the clotting rate method used in our study makes this assay even more 
sensitive to polymerization defects than the thrombin clotting time. The freeze-drying 
process may also alter the turbidity of the plasma samples (173), which may induce 
discrepancies in results obtained by the two assays. The fibrinogen concentration is 
calculated after spectrophotometrically measuring the absorption at 280 nm and 
correcting for extraneous absorption at 320 nm and 360 nm. Samples with optical 
densities (OD) at 320 nm exceeding 10% of OD 280 may underestimate the fibrinogen 
concentration. Freeze drying of the plasma samples had little effect of the turbidity in our 
study ( OD320 < 10% of OD280), and the freeze drying process did not affect the results 
obtained by the clottability assay compared to fresh frozen samples. To investigate the 
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effect of using a freeze-dried plasma standard compared to a fresh-frozen standard, the 
fibrinogen concentrations in plasma samples from individuals with a wide range of 
fibrinogen concentrations were determined using the clotting-rate assay. Significantly 
higher fibrinogen concentrations were obtained using the freeze-dried calibration plasma 
compared to corresponding fresh-frozen plasma (mean 0.04 g/l, 95% CI 0.006-0.08, 
p=0.02). The difference is small, however, and probably negligible in every-day clinical 
practice. In epidemiological studies, however, when comparing minor differences in 
fibrinogen concentrations, the influence of using freeze-dried calibration plasmas should 
be taken into consideration. The 1st fibrinogen standard was replaced in 2000 by the 2nd
International Standard for Fibrinogen (coded 98/612) prepared by the UK NIBSC and 
recommended by the ISTH fibrinogen subcommittee. The fibrinogen content of this 
standard was determined using an automated clotting-rate assay (173). 
Paper II 
In paper II we compared the plasma fibrinogen concentrations in patients undergoing 
major elective surgery obtained by a commonly used clotting rate assay (166), with a total 
clottable protein assay according to a modification of the method described by Jacobsson (165). 
Holm and Godal had previously shown that the HMW-/LMW-fibrinogen ratio increases rapidly 
during acute-phase conditions such as myocardial infarction and major surgery (201), and that 
the thrombin clotting times of  LMW- and LMW`-fibrinogen were prolonged compared to 
HMW-fibrinogen due to altered polymerization properties of the 3 fibrinogen fractions (63). The 
clotting rate assay procedure implies the addition of a high concentration of thrombin (final 
concentration 33 NIH U/ml), with a subsequent rapid release of fibrinopeptide A (FPA), 
resulting in a clotting rate depending on fibrinogen concentration and the polymerization 
properties of the fibrin monomers. A high correlation between the divergence in fibrinogen 
concentrations obtained by the two methods and the HMW-fibrinogen level was found (r = 0.81), 
indicating that the increase in HMW-fibrinogen may be an important contributor to the observed 
discrepancy.
Both fibrinogen assays used in the study have been extensively validated previously 
(165;166), and the precision of the two assay was good (intra assay CVs were 1.2-3.2% 
and 1.5-1.6% for the clotting rate and the clottability assays respectively). All samples 
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from each patient were assayed on the same day and by the same operator, thus reducing 
between-days variability. Acute-phase conditions affects the phosphorylation of FPA, 
which may increase from the normal 25-30% to over 50% (141). This has been suggested 
to affect the release rate of FPA. However, a more effective release of phosphorylated 
FPA than of FPA would probably have a limited effect on our results since high thrombin 
concentrations are added to diluted plasma. The blood samples were obtained from non-
fasting patients. Although it is clear that lipoproteins are included in fibrin clots obtained 
from lipemic plasma (165), the error in fibrinogen determination of lipemic plasma 
samples is small, providing that correction for “extraneous absorption” is made (165). All 
clottability measurements in our study were done at 280 nm wavelength, correcting for 
extraneous absorption at 320 and 360 nm. Furthermore, all plasma samples were visually 
inspected and none found to be lipemic. 
The results illustrate that variations in the HMW-/LMW-fibrinogen ratio may affect 
results obtained by a clotting rate assay, and contribute to discrepancies between methods 
reflecting the total clottability of fibrinogen and assays reflecting the functional state of 
fibrinogen.
Paper III 
In paper III we investigated the influence of the 3 major fibrinogen subfractions on the 
viscosity of native fibrinogen, and found that the viscosity of high molecular weight 
(HMW-) fibrinogen did not differ from that of low molecular weight (LMW)-, or very 
low molecular weight (LMW`) fibrinogen. This implies that degradation of the C-
terminal end of one- (LMW-fibrinogen) or both (LMW`-fibrinogen) Į-chains of the 
fibrinogen molecule, representing a loss in molecular weight of 35 kDa (10% of native 
weight) and 70 kDa (20 % of native weight,) respectively, does not significantly reduce 
the viscosity of fibrinogen. Fibrinogen is a major determinant of plasma viscosity 
(134;135). Thus, altered plasma viscosity attributable to increased fibrinogen levels in 
acute-phase conditions is not related to concomitant changes in the distribution of the 
major fibrinogen subfractions. At equal concentrations the size and shape of proteins 
determine their effect on plasma viscosity. Normally, the ĮC domain of the fibrinogen 
molecule extends from the D region, parallel to the coiled-coil of the AĮ-, Bȕ- and Ȗ-
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chains, interacting with the central region of the molecule or forming intra-molecular ĮC-
ĮC connections (29;30). Following cleavage of FPB the ĮC domains dissociate from the 
central region and become available for inter-molecular ĮC-ĮC connections (30). The 
lack of effect on fibrinogen viscosity following the loss of the ĮC-domains may indicate 
that the ĮC-domain is of minor importance to the overall shape of the fibrinogen 
molecule. Potential sources of error in this study comprise impurities of the isolated 
fibrinogen fractions. Separation of the fibrinogen fractions was performed by gradual 
precipitation of a purified fibrinogen solution, and the purity of the subfractions 
determined by sodium dodecyl sulphate (SDS) gel electrophoresis. The HMW-fibrinogen 
fraction was contaminated with 1% LMW. The LMW fraction contained 96% LMW- and 
4% LMW’-fibrinogen, and the LMW’ -fraction contained 90% LMW’-, and 10% HMW- 
and LMW-fibrinogen. The reason why the LMW`-fibrinogen contained HMW-fibrinogen 
and the LMW-fibrinogen fraction did not is unclear. Possibly, the higher ammonium 
sulphate concentration needed to precipitate the LMW`-fibrinogen fraction may have 
promoted a more effective precipitation of the remaining HMW-fibrinogen in the 
solution. Contamination of the fibrinogen solutions with soluble fibrin and other low 
solubility complexes were reduced by leaving the dialyzed fractions at 4 °C for 24 h and 
removing insoluble material following centrifugation. Remaining contaminations with 
proteins such as fibronectin represent potential sources of error. Fibronectin is a common 
contaminant in purified fibrinogen solutions, and it is up-concentrated during the 
fibrinogen precipitation procedure (202). The fibronectin concentrations in the fibrinogen 
subfractions in our study were low; 1.8 ȝg/g fibrinogen (HMW fraction), 6.0 ȝg/g
fibrinogen (LMW fraction) and 26 ȝg/g fibrinogen (LMW` fraction). Furthermore, the 
specific viscosity of fibrinogen is significantly higher than that of other plasma proteins. 
Thus, protein contamination of the LMW`-fibrinogen fraction would reduce the viscosity. 
No differences in viscosity levels in the 3 fibrinogen fractions were observed in our 
study. The intra-assay CV for the quantification of the fibrinogen fractions was 1.8%, 
indicating a high precision for the electrophoresis and densitometric scanning procedures. 
Adding EDTA, a commonly used anticoagulant, to purified native fibrinogen did not 
affect the viscosity despite a significant increase in thrombin clotting time. EDTA is a 
chelating agent which effectively removes calcium. Calcium ions are essential to preserve 
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the structure and function of the fibrinogen molecule (200;203;204). Removal of calcium 
facilitates denaturation of fibrinogen as reflected by increased thrombin clotting time 
(33;200). Denaturation of proteins has been closely associated with changes in viscosity 
(205), but the denaturation of fibrinogen induced by EDTA does not significantly affect 
the viscosity of plasma compared to heparin anticoagulated plasma. 
Paper IV 
In paper IV we wanted to investigate the effect of a daily glass of red wine on plasma 
viscosity, fibrinogen levels and the distribution of the major fibrinogen subfractions. 
Moderate alcohol consumption has been linked to reduced risk of ischemic heart disease 
(206-208). A beneficial effect on haemostatic factors such as fibrinogen and plasma 
viscosity has been launched as possible contributors to this risk reduction. The study was 
a prospective, randomized crossover trial, and a sub-study of the work by Retterstøl and 
colleagues from 2005 (209). The study recruited 92 healthy men (35%) and women 
(65%). Smoking significantly affects fibrinogen levels and plasma viscosity, and only 
non-smokers were recruited in the trial (210). The crossover design implies that the 
volunteers were randomized to start with 3 weeks of red wine drinking or abstention, and 
subsequently crossed over to the other intervention. This design is particularly effective 
in intervention studies, because it enables each individual to be its own control, and, thus, 
eliminates between-subject variation. This increases the statistical power of the study 
compared to parallel group designs, and requires a smaller sample size. Crossover studies 
are, however, sensitive to carryover effects. As illustrated in figure 1 and 2 in paper IV, 
the observed mean plasma viscosity and fibrinogen concentration following the 
abstention period differed in the subgroups, indicating a prolonged effect of wine 
drinking on plasma viscosity. This effect and the fact that the majority of the participants 
were moderate alcohol consumers at the time of inclusion (median consumption 1-3 units 
per week) may explain why no difference in plasma fibrinogen levels were observed in 
the group starting with wine drinking. The prolonged effect of wine drinking on plasma 
viscosity was an unexpected but interesting finding in the study, which, to our 
knowledge, has not previously been discussed. Including abstention periods at the 
beginning of the study and between each treatment period, might have reduced this 
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effect. Due to the prolonged viscosity lowering effect of red wine, the results from each 
subgroup were analyzed and presented separately.  For logistical reasons, the alcohol 
intake in the study was not supervised. Although the importance of complying with the 
study protocol was carefully explained to the participants, lack of adherence to the 
scheduled intervention represents a potential confounder in the study.  Self reported 
compliance was, however, good. Five participants reported missing 1-2 days in the wine 
period, and two participants consumed 1-2 units of alcohol during the abstention period, 
which may have attenuated the effects on viscosity and fibrinogen levels, and potentially 
reduced the observed differences between the wine drinking- and abstention periods.
Although the participants were encouraged to maintain a normal diet, data concerning 
diet and physical exercise were not recorded. However, only ethanol consumption seems 
to have a clear and consistent effect on plasma fibrinogen levels. Other dietary 
components seem to have modest or no effects (for review see (211)). Thus, changes in 
diet during the study period do probably not represent a potential confounder on 
fibrinogen levels. Blood sampling were performed in non-fasting subjects. The effects of 
meals seem to have little effect on plasma viscosity measurements, however (212;213).  
Plasma viscosity was determined by a “falling ball” viscometer. The intra assay CV of 
the assay was 0.41%, indicating a high precision in measurements. Blood sampling and 
measurements were performed according to international guidelines, except that frozen 
plasma samples were used. No statistically significant differences in viscosity between 
corresponding fresh and thawed frozen plasma samples were found in our study. 
Differences in study populations, smoking and alcohol consumption, fibrinogen levels 
and different assays used for viscosity determination, may contribute to differences in 
observed plasma viscosity in different trials (214-216).  Increased plasma viscosity and 
fibrinogen levels have been identified as independent markers of increased risk of CHD 
(217). In addition to raising plasma high density lipoprotein (HDL) levels, reduced 
plasma viscosity and fibrinogen levels may contribute to the observed health benefits 
associated with moderate red wine consumption. 
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Paper V
Close interaction exists between the inflammatory- and coagulations systems. Thus, local 
and systemic inflammation may induce initiation of the coagulation system, and 
activation of coagulation may, on the other hand, affect inflammatory activity (for review 
see (218)). Tissue factor (TF) plays a central role in the inflammation induced activation 
of coagulation, but the interactions between the two systems also include thrombin, 
protein C and the fibrinolytic system. On the other hand, proinflammatory cytokines and 
chemokines have been shown to promote the expression of TF and induce coagulation 
(219).
In paper V we found that purified fibrinogen and fibrin significantly upregulated mRNA 
and synthesis of the proinflammatory cytokines IL-6 and TNF-Į in isolated peripheral 
blood mononuclear cells (PBMC). Fibrinogen and fibrin were equally effective, and no 
difference in stimulatory effects were found between unfractioned fibrinogen containing 
59% HMW-, 39% LMW- and 2% LMW`-fibrinogen and purified HMW-fibrinogen 
containing 99% HMW- and 1% LMW-fibrinogen, suggesting that the C-terminal Į-chain
is not essential for the stimulatory effects. Altered HMW-/LMW ratios, thus, seem to be 
of minor importance for the potential proinflammatory effects of fibrinogen/fibrin. 
Higher fibrin(ogen) concentrations in the cell cultures yielded higher cytokine levels in 
the supernatant, indicating a dose dependant effect.
Previous reports have indicated that fibrinogen may affect leukocyte function 
(182;183;220-224), and Perez and coworkers found that fibrin and fibrinogen may induce 
synthesis of IL-1ȕ from PBMC (184).  The integrins CD11b/CD18 (Mac-1) and, to a less 
extent, CD11c/CD18, seem to be the principal fibrinogen receptors on monocytes, 
macrophages and lymphocytes.  The fibrin(ogen) Ȗ-chain (Ȗ190-202 and Ȗ377-395 ) contains 
the putative recognition sites for the integrins (225). Fibrinogen mediated activation of 
transcriptional factors such as NF-kappa B have been implicated in the activation process 
(226;227). Circulating PBMC are continuously exposed to fibrinogen in vivo without 
producing significant levels of proinflammatory cytokines in healthy individuals (228). 
Thus, cell activation seems to be required for the cells to express CD11b/CD18 and thus 
facilitate cell-fibrinogen interaction (228;229).
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We used cultured PBMC isolated from whole blood to study the effects of fibrinogen and 
fibrin. PBMC includes monocytes and lymphocytes and are commonly used to study the 
effect of stimulants ex vivo. The advantage of using isolated cell cultures is that the 
effects of stimulatory or inhibitory agents on specific cells can be studied in detail. Since 
cytokines are mainly released and consumed locally at the site of inflammation, cytokine 
levels in peripheral blood often do not reflect local inflammation and, thus, can not be 
used to study local inflammatory mechanisms. The disadvantages of using isolated cell 
cultures include removal of cytokines and other stimulatory or inhibitory factors during 
the isolation process. These factors may play essential roles in the inflammatory response 
in vivo. Furthermore, the isolation process and subsequent incubation may in it self 
activate the cells and make them more susceptible to stimulants (230). Therefore, 
inflammatory responses to stimulants observed in isolated cell cultures do not necessarily 
reflect the physiological responses in vivo. Whole blood systems may be better in 
reproducing the natural cell environment, allowing interaction between different cells, 
and including natural occurring stimulatory or inhibitory factors. Several potential 
confounding factors may have affected the results from our study. Cell activation and 
synthesis of proinflammatory cytokine due to lipopolysaccarids (LPS) or bacteria 
contamination of collection tubes, reagents and buffers during the blood sampling or cell 
isolation process represent an important potential source of error when studying 
inflammatory responses in cell cultures (231-233). Blood samples in our study were 
drawn from apparently healthy subjects who had not used any medication two weeks 
prior to blood sampling. We used sterile, endotoxin tested sampling tubes and buffers, 
and the PBMC isolation procedure was performed under strict sterile conditions. When 
present, LPS contamination was removed using an endotoxin removal resin (End-X® B-
52, Associates of Cape Cod, Woods Hole, MA, USA). Before used, all buffers, culture 
media, electrolyte solutions and fibrinogen solutions were tested for LPS contamination 
using a highly sensitive chromogenic end-point assay with a lower detection limit of 1 
pg/ml LPS (0.01 EU/ml), and deemed LPS free. LPS contamination below the detection 
limit of the assay, although not capable of inducing significant cytokine synthesis, may 
have contributed to cell activation. Following isolation, the cell cultures were incubated 
at 37 °C for 10 hours, before frozen at -70 °C. Activation of cells during the isolation 
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procedures and incubation period is well known. Previous trials have demonstrated 
changes in steady-state expression levels of cytokine mRNAs such as IL-1, IL-6, and 
TNF-Į during culture of human PBMC, even under control conditions (230).  
Spontaneous in vitro aggregation or adherence to the culture wells might also promote 
activation and be of relevance in gene expression studies. Cytokine synthesis in our 
control cell cultures were either absent or weakly detectable. Importantly, however, all 
cells were exposed to the same isolating and incubation procedures, and supernatant from 
cells incubated with fibrinogen or fibrin contained significantly higher cytokine levels 
than controls. Furthermore, incubating cells with liquor from the defibrinated fibrinogen 
solutions (after clotting with thrombin) did not induce cell cytokine synthesis, indicating 
that fibrinogen indeed promoted mRNA upregulation and cytokine synthesis from the 
cells.
Variations in mRNA upregulation and cytokine production in cell cultures from different 
donors might be attributable to variations in activation or the number of monocytes in the 
cell cultures. All cell cultures contained significant numbers of granulocytes (25, 75 
percentile: 7, 16%), which might also have affected our results. However, previous cell 
stimulation studies indicate a strong correlation between the production levels of 
proinflammatory cytokines like IL-1ȕ, IL-6, and TNF-Į  and the number of monocytes, 
indicating that monocytes may be the principal source of synthesis of these cytokines in 
cell cultures (228).
Limited data exists on proinflammatory effects of fibrinogen and fibrin in vivo. It is clear 
that fibrinogen plays a central role in the inflammatory response to implanted 
biomaterials (187;188), and animal studies have suggested that local deposition of fibrin 
sustains inflammation in some inflammatory diseases (234). Due to the close interaction 
between fibrin(ogen) and inflammatory cells in acute and chronic inflammatory diseases 
in vivo (235-237), possible proinflammatory effects of fibrin(ogen) might modify the 
inflammatory responses in a wide range of inflammatory disorders. Further research is 
needed, however, to elucidate the interaction between fibrin(ogen) and inflammatory 
cells, and determine potential proinflammatory effects. Experiments should include 
whole blood systems as well as isolated cell systems including monocytes/macrophages 
and lymphocyte subclasses.  
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9. CONCLUSIONS 
1. Freeze-drying of human plasma decreases its clotting rate. When using a clotting rate 
fibrinogen assay calibrated with freeze-dried plasma, higher fibrinogen concentrations are 
obtained compared to using fresh-frozen plasma (paper I). 
2. Higher plasma fibrinogen concentrations are obtained using a clotting rate fibrinogen 
assay than a total clottable protein assay following major surgery. The discrepancy in 
results from the two methods is correlated to an increased HMW-fibrinogen fraction 
(paper II). 
3. The viscosity of the 3 main fibrinogen subfractions HMW-, LMW-, and LMW`-
fibrinogen do not differ from that of native fibrinogen. Adding EDTA to purified 
fibrinogen induces denaturation of the fibrinogen molecule as reflected by prolonged 
thrombin clotting time, but does not affect viscosity. The use of EDTA as plasma 
anticoagulant does not significantly affect plasma viscosity compared to Heparin 
anticoagulated plasma (paper III). 
4. A daily glass of red wine induces a prolonged reduction in plasma viscosity. 
Fibrinogen levels are also reduced when preceded by an abstention period (paper IV). 
5. Fibrinogen upregulates mRNA and synthesis of the proinflammatory cytokines IL-6 
and TNF-Į in isolated peripheral blood mononuclear cells. Fibrinogen and fibrin are 
equally effective in promoting cytokine synthesis, and altered HMW-LMW-fibrinogen 
ratio does not alter the proinflammatory effects (paper V). 
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